Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Equity Average (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Equity Average for 9 consecutive years, with $630.1 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 4.38% to $630.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $630.1 million through Dec 2025, up 4.38% year-over-year, with the annual reading at $645.0 million for FY2025, 27.47% up from the prior year.
  • Equity Average hit $630.1 million in Q4 2025 for Protagonist Therapeutics, down from $656.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $682.2 million in Q1 2025 to a low of $215.9 million in Q1 2023.
  • Historically, Equity Average has averaged $409.2 million across 5 years, with a median of $317.1 million in 2021.
  • Biggest five-year swings in Equity Average: soared 277.86% in 2021 and later fell 28.25% in 2023.
  • Year by year, Equity Average stood at $314.8 million in 2021, then decreased by 27.07% to $229.6 million in 2022, then skyrocketed by 39.11% to $319.4 million in 2023, then skyrocketed by 88.97% to $603.6 million in 2024, then increased by 4.38% to $630.1 million in 2025.
  • Business Quant data shows Equity Average for PTGX at $630.1 million in Q4 2025, $656.7 million in Q3 2025, and $678.5 million in Q2 2025.